JP2018504894A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018504894A5 JP2018504894A5 JP2017532639A JP2017532639A JP2018504894A5 JP 2018504894 A5 JP2018504894 A5 JP 2018504894A5 JP 2017532639 A JP2017532639 A JP 2017532639A JP 2017532639 A JP2017532639 A JP 2017532639A JP 2018504894 A5 JP2018504894 A5 JP 2018504894A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- car
- antibody
- nucleic acid
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 24
- 210000004027 cell Anatomy 0.000 claims description 20
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 230000004068 intracellular signaling Effects 0.000 claims description 8
- 229920001184 polypeptide Polymers 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 4
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 4
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 4
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 4
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 claims description 4
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 4
- 108700012439 CA9 Proteins 0.000 claims description 4
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 claims description 4
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 claims description 4
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims description 4
- 241000710831 Flavivirus Species 0.000 claims description 4
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 4
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims description 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 4
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 4
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims description 4
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 4
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 4
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 4
- 241000315672 SARS coronavirus Species 0.000 claims description 4
- 102100035721 Syndecan-1 Human genes 0.000 claims description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 4
- 230000000139 costimulatory effect Effects 0.000 claims description 4
- 241000712461 unidentified influenza virus Species 0.000 claims description 4
- -1 ICOS Proteins 0.000 claims description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 claims description 2
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022011441A JP7548950B2 (ja) | 2014-12-19 | 2022-01-28 | キメラ抗原受容体およびその使用方法 |
| JP2024147204A JP2024163140A (ja) | 2014-12-19 | 2024-08-29 | キメラ抗原受容体およびその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462094625P | 2014-12-19 | 2014-12-19 | |
| US62/094,625 | 2014-12-19 | ||
| US201562252083P | 2015-11-06 | 2015-11-06 | |
| US62/252,083 | 2015-11-06 | ||
| PCT/US2015/067225 WO2016100985A2 (en) | 2014-12-19 | 2015-12-21 | Chimeric antigen receptors and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022011441A Division JP7548950B2 (ja) | 2014-12-19 | 2022-01-28 | キメラ抗原受容体およびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018504894A JP2018504894A (ja) | 2018-02-22 |
| JP2018504894A5 true JP2018504894A5 (cg-RX-API-DMAC7.html) | 2019-02-07 |
Family
ID=55229842
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017532639A Pending JP2018504894A (ja) | 2014-12-19 | 2015-12-21 | キメラ抗原受容体およびその使用方法 |
| JP2022011441A Active JP7548950B2 (ja) | 2014-12-19 | 2022-01-28 | キメラ抗原受容体およびその使用方法 |
| JP2024147204A Pending JP2024163140A (ja) | 2014-12-19 | 2024-08-29 | キメラ抗原受容体およびその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022011441A Active JP7548950B2 (ja) | 2014-12-19 | 2022-01-28 | キメラ抗原受容体およびその使用方法 |
| JP2024147204A Pending JP2024163140A (ja) | 2014-12-19 | 2024-08-29 | キメラ抗原受容体およびその使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20170362297A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3233900A2 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2018504894A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20170090506A (cg-RX-API-DMAC7.html) |
| CN (1) | CN108064252A (cg-RX-API-DMAC7.html) |
| AU (4) | AU2015364245B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112017013176A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2968412A1 (cg-RX-API-DMAC7.html) |
| IL (3) | IL252295B2 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2017125531A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016100985A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104994873B (zh) * | 2012-10-04 | 2017-12-22 | 达纳－法伯癌症研究所公司 | 人单克隆抗‑pd‑l1抗体和使用方法 |
| WO2014117121A1 (en) | 2013-01-28 | 2014-07-31 | St. Jude Children's Research Hospital, Inc. | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
| KR20160145813A (ko) * | 2014-04-25 | 2016-12-20 | 다나-파버 캔서 인스티튜트 인크. | 중동 호흡기 증후군 코로나바이러스 중화 항체 및 이의 사용 방법 |
| CA2948462A1 (en) | 2014-05-15 | 2015-11-19 | National University Of Singapore | Modified natural killer cells and uses thereof |
| CA2949998A1 (en) | 2014-05-28 | 2015-12-03 | Agenus Inc. | Anti-gitr antibodies and methods of use thereof |
| CN108883173B (zh) | 2015-12-02 | 2022-09-06 | 阿吉纳斯公司 | 抗体和其使用方法 |
| EP3420000A1 (en) | 2016-02-25 | 2019-01-02 | Cell Medica Switzerland AG | Modified cells for immunotherapy |
| WO2017165683A1 (en) * | 2016-03-23 | 2017-09-28 | Novartis Ag | Cell secreted minibodies and uses thereof |
| CA3027204A1 (en) * | 2016-06-29 | 2018-01-04 | Checkpoint Therapeutics, Inc. | Pd-l1-specific antibodies and methods of using the same |
| ES3000676T3 (en) | 2016-07-07 | 2025-03-03 | Iovance Biotherapeutics Inc | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof |
| JP6908710B2 (ja) * | 2016-09-21 | 2021-07-28 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | ケモカイン受容体ｃｃｒ４を標的にするキメラ抗原受容体（ｃａｒ）およびその使用 |
| ES2811500T3 (es) | 2016-10-04 | 2021-03-12 | Prec Biosciences Inc | Dominios coestimuladores para su uso en células genéticamente modificadas |
| WO2018089628A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
| WO2018089829A1 (en) | 2016-11-10 | 2018-05-17 | Fortis Therapeutics, Inc. | Cd46-specific effector cells and uses thereof |
| CN108148862B (zh) * | 2016-12-05 | 2019-03-08 | 上海优卡迪生物医药科技有限公司 | 一种封闭pdl1的用于抑制免疫逃脱的car-t转基因载体及其构建方法和应用 |
| KR102624509B1 (ko) | 2017-03-27 | 2024-01-12 | 싱가포르국립대학교 | 자연 살해 세포의 ex vivo 확장 및 활성화를 위한 자극성 세포주 |
| EP3600356A4 (en) | 2017-03-27 | 2020-12-23 | National University of Singapore | TRUNCATED NKG2D CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLER CELL IMMUNOTHERAPY |
| CN110914289B (zh) | 2017-05-12 | 2024-05-14 | 克里斯珀医疗股份公司 | 用于工程化细胞的材料和方法及其在免疫肿瘤学中的用途 |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| CN107337736B (zh) * | 2017-06-06 | 2019-07-26 | 上海优卡迪生物医药科技有限公司 | Octs-car双靶向嵌合抗原受体、编码基因、重组表达载体及其构建和应用 |
| JP7360174B2 (ja) | 2018-02-09 | 2023-10-12 | ナショナル ユニヴァーシティー オブ シンガポール | ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用 |
| EP3765070A4 (en) * | 2018-03-14 | 2021-12-15 | Dana-Farber Cancer Institute, Inc. | SPECIFICALLY MODIFIED CELLS, T-LYMPHOCYTE IMMUNE MODULATION ANTIBODIES AND THEIR USE PROCEDURES |
| JP7334985B2 (ja) | 2018-04-02 | 2023-08-29 | ナショナル ユニヴァーシティー オブ シンガポール | 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和 |
| JP2021521778A (ja) * | 2018-04-16 | 2021-08-30 | メモリアル スローン ケタリング キャンサー センター | Ｔ細胞枯渇、およびそれに関連する方法および組成物 |
| PE20210666A1 (es) | 2018-05-11 | 2021-03-31 | Crispr Therapeutics Ag | Metodos y composiciones para tratar el cancer |
| JP7447388B2 (ja) * | 2018-07-13 | 2024-03-12 | ナンジン レジェンド バイオテック カンパニー，リミテッド | 感染性疾患の治療のための共受容体システム |
| AU2019310855A1 (en) * | 2018-07-24 | 2021-03-11 | Crage Medical Co., Limited | Method for treating tumor using immune effector cell |
| CN112601758A (zh) | 2018-08-29 | 2021-04-02 | 新加坡国立大学 | 特异性刺激经基因修饰免疫细胞的存活和扩增的方法 |
| CA3113896A1 (en) | 2018-09-27 | 2020-04-02 | Autolus Limited | Chimeric antigen receptor |
| EP3886877A4 (en) * | 2018-11-26 | 2022-08-24 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| CN118546959A (zh) | 2019-03-05 | 2024-08-27 | 恩卡尔塔公司 | Cd19定向性嵌合抗原受体及其在免疫疗法中的用途 |
| US11104732B2 (en) * | 2019-04-24 | 2021-08-31 | Innovative Cellular Therapeutics Holdings, Ltd. | Reducing immune inhibition induced by SIGLEC-15 |
| WO2020219843A1 (en) * | 2019-04-26 | 2020-10-29 | The University Of North Carolina At Chapel Hill | Chimeric antigen receptor constructs and their use in car-t cells |
| SG11202111130SA (en) | 2019-04-30 | 2021-11-29 | Senti Biosciences Inc | Chimeric receptors and methods of use thereof |
| EA202192975A1 (ru) | 2019-04-30 | 2022-02-01 | Криспр Терапьютикс Аг | Аллогенная клеточная терапия b-клеточных злокачественных новообразований с применением генетически сконструированных т-клеток, нацеливающихся на cd19 |
| CA3141926A1 (en) | 2019-06-14 | 2020-12-17 | Dana-Farber Cancer Institute, Inc. | Antibodies against muc1 and methods of use thereof |
| CN114286683B (zh) * | 2019-07-17 | 2024-10-01 | 新加坡国立大学 | 由免疫细胞合成和分泌的功能性结合物 |
| WO2021016606A1 (en) * | 2019-07-24 | 2021-01-28 | Eureka Therapeutics, Inc. | Chimeric antigen receptor t cells and uses thereof |
| CA3159308A1 (en) * | 2019-12-02 | 2021-06-10 | Wayne A. Marasco | Antibodies against pd-l1 and methods of use thereof |
| WO2021142835A1 (zh) * | 2020-01-19 | 2021-07-22 | 北京卡替医疗技术有限公司 | 一种提升免疫细胞功能的增强受体 |
| EP4148065A4 (en) * | 2020-05-08 | 2024-05-29 | SMT Bio Co., Ltd. | Chimeric antigen receptor for treatment of cancer |
| IL300528A (en) | 2020-08-07 | 2023-04-01 | Fortis Therapeutics Inc | Immune conjugates targeting cd46 and methods of using them |
| WO2022173950A1 (en) * | 2021-02-11 | 2022-08-18 | The Trustees Of The University Of Pennsylvania | Ccr4-targeting chimeric antigen receptor cell therapy |
| KR20220136876A (ko) | 2021-04-01 | 2022-10-11 | 주식회사 이뮤노로지컬디자이닝랩 | 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도 |
| BR112023000666A2 (pt) * | 2021-04-12 | 2023-10-24 | Academia Sinica | Imunógeno, composição imunogênica, método para induzir uma resposta imune contra um coronavírus 2 da síndrome respiratória aguda grave e uso da composição imunogênica |
| KR20220144000A (ko) | 2021-04-16 | 2022-10-26 | 주식회사 이뮤노로지컬디자이닝랩 | Programmed death-ligand 1(PD-L1)에 특이적으로 결합하는 키메릭 항원 수용체 및 이의 용도 |
| EP4334354A1 (en) | 2021-05-06 | 2024-03-13 | Dana-Farber Cancer Institute, Inc. | Antibodies against alk and methods of use thereof |
| KR20230089464A (ko) | 2021-12-13 | 2023-06-20 | 주식회사 이뮤노로지컬디자이닝랩 | 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도 |
| KR20230089462A (ko) | 2021-12-13 | 2023-06-20 | 주식회사 이뮤노로지컬디자이닝랩 | 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도 |
| EP4491633A1 (en) * | 2022-03-08 | 2025-01-15 | Vaxcell-Bio Co., Ltd. | Pd-l1-specific chimeric antigen receptor and immune cell comprising same |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| US20050113564A1 (en) * | 2003-11-05 | 2005-05-26 | St. Jude Children's Research Hospital | Chimeric receptors with 4-1BB stimulatory signaling domain |
| CN1914226B (zh) | 2003-11-25 | 2012-02-01 | 达纳-法伯癌症研究院有限公司 | SARS-CoV抗体及其使用方法 |
| EP1871807B1 (en) | 2005-02-18 | 2012-11-28 | Dana-Farber Cancer Institute, Inc. | Antibodies against cxcr4 and methods of use thereof |
| CA2632094C (en) | 2005-12-02 | 2015-01-27 | Wayne A. Marasco | Carbonic anhydrase ix (g250) antibodies and methods of use thereof |
| WO2009079259A2 (en) | 2007-12-06 | 2009-06-25 | Dana-Farber Cancer Institute, Inc. | Antibodies against influenza virus and methods of use thereof |
| US8962806B2 (en) | 2007-12-28 | 2015-02-24 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
| AU2011261396B2 (en) | 2010-06-02 | 2015-11-05 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
| US9402865B2 (en) | 2011-01-18 | 2016-08-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
| EP3594245A1 (en) * | 2012-02-13 | 2020-01-15 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| EP2836239A1 (en) * | 2012-04-11 | 2015-02-18 | The United States of America, as Represented By the Secretary, Department of Health and Human Services | Chimeric antigen receptors targeting b-cell maturation antigen |
| HK1207655A1 (en) | 2012-05-04 | 2016-02-05 | Dana-Farber Cancer Institute, Inc. | Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use |
| KR20150029714A (ko) * | 2012-07-13 | 2015-03-18 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 이중특이적 항체의 공-도입에 의한 ｃａｒ 세포의 활성 증강 |
| CN104994873B (zh) * | 2012-10-04 | 2017-12-22 | 达纳－法伯癌症研究所公司 | 人单克隆抗‑pd‑l1抗体和使用方法 |
| EP3811954A1 (en) * | 2013-02-26 | 2021-04-28 | Memorial Sloan Kettering Cancer Center | Compositions and methods for immunotherapy |
| CA2901358C (en) | 2013-03-15 | 2022-07-26 | Dana-Farber Cancer Institute, Inc. | Flavivirus neutralizing antibodies and methods of use thereof |
| WO2015143194A2 (en) | 2014-03-19 | 2015-09-24 | Dana-Farber Cancer Institute, Inc. | Immunogenetic restriction on elicitation of antibodies |
| KR20160145813A (ko) | 2014-04-25 | 2016-12-20 | 다나-파버 캔서 인스티튜트 인크. | 중동 호흡기 증후군 코로나바이러스 중화 항체 및 이의 사용 방법 |
| WO2016054638A1 (en) | 2014-10-03 | 2016-04-07 | Dana-Farber Cancer Institute, Inc. | Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof |
| WO2016057488A1 (en) | 2014-10-06 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof |
| JP2018500337A (ja) * | 2014-12-19 | 2018-01-11 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 炭酸脱水酵素ｉｘ特異的キメラ抗原受容体およびその使用方法 |
| CA3002674A1 (en) * | 2015-10-30 | 2017-05-04 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
-
2015
- 2015-12-21 IL IL252295A patent/IL252295B2/en unknown
- 2015-12-21 CN CN201580069023.0A patent/CN108064252A/zh active Pending
- 2015-12-21 CA CA2968412A patent/CA2968412A1/en active Pending
- 2015-12-21 AU AU2015364245A patent/AU2015364245B2/en active Active
- 2015-12-21 JP JP2017532639A patent/JP2018504894A/ja active Pending
- 2015-12-21 US US15/537,779 patent/US20170362297A1/en not_active Abandoned
- 2015-12-21 WO PCT/US2015/067225 patent/WO2016100985A2/en not_active Ceased
- 2015-12-21 KR KR1020177020045A patent/KR20170090506A/ko active Pending
- 2015-12-21 IL IL320860A patent/IL320860A/en unknown
- 2015-12-21 BR BR112017013176-5A patent/BR112017013176A2/en not_active Application Discontinuation
- 2015-12-21 RU RU2017125531A patent/RU2017125531A/ru not_active Application Discontinuation
- 2015-12-21 EP EP15828615.3A patent/EP3233900A2/en active Pending
- 2015-12-21 IL IL302660A patent/IL302660B2/en unknown
-
2020
- 2020-06-30 AU AU2020204373A patent/AU2020204373B2/en active Active
- 2020-08-06 US US16/986,913 patent/US12195514B2/en active Active
-
2022
- 2022-01-17 AU AU2022200257A patent/AU2022200257B2/en active Active
- 2022-01-28 JP JP2022011441A patent/JP7548950B2/ja active Active
-
2024
- 2024-01-31 AU AU2024200592A patent/AU2024200592A1/en active Pending
- 2024-08-29 JP JP2024147204A patent/JP2024163140A/ja active Pending
- 2024-12-05 US US18/970,194 patent/US20250243259A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018504894A5 (cg-RX-API-DMAC7.html) | ||
| RU2017125531A (ru) | Химерные антигенные рецепторы и способы их применения | |
| HRP20240357T1 (hr) | Stanica | |
| WO2019090003A9 (en) | Chimeric antigen receptors specific for b-cell maturation antigen (bcma) | |
| FI3896091T3 (fi) | BCMA:han kohdentuvia kimeerisiä antigeenireseptoreita ja menetelmiä niiden käyttämiseksi | |
| JP2020114264A5 (cg-RX-API-DMAC7.html) | ||
| JP2018500337A5 (cg-RX-API-DMAC7.html) | ||
| HRP20191839T1 (hr) | Car ekspresijski vektor i t stanice koje eksprimiraju car | |
| JP2019527557A5 (cg-RX-API-DMAC7.html) | ||
| JP2016508518A5 (cg-RX-API-DMAC7.html) | ||
| BR112018008442A2 (pt) | receptores quiméricos contendo domínios induto-res de traf e composições e métodos relacionados | |
| MX2014010183A (es) | Composiciones y metodos para generar una poblacion persistente de celulas t utiles para el tratamiento de cancer. | |
| HK1252235A1 (zh) | 表达γ-δT细胞受体(TCR)和嵌合抗原受体(CAR)的T细胞 | |
| JP2017529851A5 (cg-RX-API-DMAC7.html) | ||
| EP4477748A3 (en) | Methods of making chimeric antigen receptor-expressing cells | |
| MX389797B (es) | Expresión transgénica regulada por fármaco. | |
| WO2016109410A3 (en) | Methods of making chimeric antigen receptor-expressing cells | |
| CO2017006808A2 (es) | Receptores de antígenos quiméricos de bcma | |
| FI4219687T3 (fi) | Menetelmiä immuunisolupopulaatioiden eristämiseksi, viljelemiseksi ja geneettiseksi muokkaamiseksi adoptiivista terapiaa varten | |
| JP2014534207A5 (cg-RX-API-DMAC7.html) | ||
| MX380109B (es) | Metodo y composiciones para inmunoterapia celular. | |
| JP2018514576A5 (cg-RX-API-DMAC7.html) | ||
| RU2018140056A (ru) | Композиции и способы с использованием т-клеток с химерным рецептором аллоантигена | |
| JP2019513394A5 (cg-RX-API-DMAC7.html) | ||
| WO2011130491A3 (en) | Methods and compositions for treating hiv |